Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699608 | 0.89 | GPR119 (0.58) | USP30GPR119NR1H2ALDH1A1CHEK2 | |
| SCHEMBL15376614 | 0.89 | GPR119 (0.58) | USP30GPR119NR1H2ALDH1A1CHEK2 | |
| SCHEMBL699609 | 0.89 | GPR119 (0.58) | USP30GPR119NR1H2ALDH1A1CHEK2 | |
| SCHEMBL30738768 | 0.89 | NR1H2 (0.51) | USP30GPR119NR1H2ALDH1A1LIPE | |
| SCHEMBL28670992 | 0.88 | USP30 (0.53) | USP30GPR119NR1H2ALDH1A1CHEK2 | |
| SCHEMBL12788093 | 0.88 | USP30 (0.53) | USP30GPR119NR1H2ALDH1A1CHEK2 | |
| SCHEMBL31753650 | 0.87 | CHEK2 (0.54) | USP30GPR119CHEK2 | |
| SCHEMBL16434828 | 0.87 | USP30 (0.52) | USP30GPR119ALDH1A1LIPE | |
| SCHEMBL14862587 | 0.87 | USP30 (0.52) | USP30GPR119NR1H2ALDH1A1CHEK2 | |
| SCHEMBL3343250 | 0.87 | USP30 (0.52) | USP30GPR119NR1H2ALDH1A1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023287736-A1 | NOVEL BIS-AMIDE CONTAINING COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287736-A1 | NOVEL BIS-AMIDE CONTAINING COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | disclosed |
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| CN-107001259-B | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3564232-A1 | BMP-SIGNAL-INHIBITING COMPOUND | Riken (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9758511-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| WO-2013170112-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013170113-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013170113-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-2089397-B1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011142359-A1 | SPIRO COMPOUND AND DRUG FOR ACTIVATING ADIPONECTIN RECEPTOR | 日産化学工業株式会社 (JP) | 2011-11-17 | — | — | WO | disclosed |
| EP-1507530-B1 | DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| EP-1507530-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6818663-B2 | AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS | HOFFMANN-LA ROCHES | 2004-11-16 | — | — | US | disclosed |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CHU XIN-JIE (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003097048-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | USP30 4094/4885GPR119 1381/4885NR1H2 1047/4885 |
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | USP30 1754/4885GPR119 6/4885NR1H2 185/4885 |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | BMP1, BMP2, BMPR2 | USP30 4215/4885GPR119 1267/4885NR1H2 738/4885 |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CDK4, CDK1, CDK2 | USP30 3539/4885GPR119 2534/4885NR1H2 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.